Analiza występowania udarów u chorych uczestniczących w badaniu ATHENA Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2011
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Dąbrowski , R. (2011). Analiza występowania udarów u chorych uczestniczących w badaniu ATHENA. Medycyna Faktów , 4(1(10), 70-72. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2552
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Hohnloser S.H., Crijns H.J., van Eickels M. et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 2009; 360: 668-678.
2. Burkart F., Pfisterer M., Kiowski W. et al.: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J. Am. Coll. Cardiol. 1990; 16: 1711-8.
3. Ceremużyński L., Kleczar E., Krzeminska-Pakula M. et al.: Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo- controlled, pilot study. J. Am. Coll. Cardiol. 1992; 20: 1056-1062.
4. Doval H.C., Nul D.R., Grancelli H.O. et al.: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-8.
5. Cairns J.A., Connolly S.J., Roberts R., Gent M.: Randomized trial of outcomes after myocardial infarction in patients with frequent to repetitive ventricular premature depolarizations. CAMIAT. Lancet 1997; 349: 675-682.
6. Julian D.G., Camm A.J., Frangin G. et al.: Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674.
7. Bardy G.H., Lee K.L., Mark D.B. et al.: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Inves Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 2005; 352: 225-237.
8. Guillemare E., Marion A., Nisato D., Gautier P.: Inhibitory effects of dronedarone on muscarinic K†current in guinea pig atrial cells. J. Cardiovasc. Pharmacol. 2000; 36: 802-805.
9. Connolly S.J., Crijns H.J., Torp-Pedersen C. et al.: Analysis of stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. Circulation 2009; 120: 1174-80.
10. Ezekowitz M.D., Koti M.J., Fulton B.: Reducing stroke rates in patients with atrial fibrillation: How low can we go? Circulation 2009; 120: 1169-1170.
11. Sherman D.G., Kim S.G., Boop B.S. et al.: Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch. Intern. Med. 2005; 165: 1185-1191.
12. de Denus S., Sanoski C.A., Carlsson J. et al.: Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch. Intern. Med. 2005; 165: 258-262.
2. Burkart F., Pfisterer M., Kiowski W. et al.: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J. Am. Coll. Cardiol. 1990; 16: 1711-8.
3. Ceremużyński L., Kleczar E., Krzeminska-Pakula M. et al.: Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo- controlled, pilot study. J. Am. Coll. Cardiol. 1992; 20: 1056-1062.
4. Doval H.C., Nul D.R., Grancelli H.O. et al.: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-8.
5. Cairns J.A., Connolly S.J., Roberts R., Gent M.: Randomized trial of outcomes after myocardial infarction in patients with frequent to repetitive ventricular premature depolarizations. CAMIAT. Lancet 1997; 349: 675-682.
6. Julian D.G., Camm A.J., Frangin G. et al.: Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674.
7. Bardy G.H., Lee K.L., Mark D.B. et al.: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Inves Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 2005; 352: 225-237.
8. Guillemare E., Marion A., Nisato D., Gautier P.: Inhibitory effects of dronedarone on muscarinic K†current in guinea pig atrial cells. J. Cardiovasc. Pharmacol. 2000; 36: 802-805.
9. Connolly S.J., Crijns H.J., Torp-Pedersen C. et al.: Analysis of stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. Circulation 2009; 120: 1174-80.
10. Ezekowitz M.D., Koti M.J., Fulton B.: Reducing stroke rates in patients with atrial fibrillation: How low can we go? Circulation 2009; 120: 1169-1170.
11. Sherman D.G., Kim S.G., Boop B.S. et al.: Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch. Intern. Med. 2005; 165: 1185-1191.
12. de Denus S., Sanoski C.A., Carlsson J. et al.: Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch. Intern. Med. 2005; 165: 258-262.